Targeting CD38 alleviates tumor-induced immunosuppression

Oncotarget. 2017 Dec 26;8(68):112166-112167. doi: 10.18632/oncotarget.22992. eCollection 2017 Dec 22.

Authors

Yu-Tzu Tai¹, Kenneth C Anderson¹

Affiliation

¹ The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

No abstract available

Keywords: CD38; Multiple myeloma; bone marrow microenvironment; daratumumab; immunomodulatory activity; isatuximab.

Publication types

Editorial